Hugel Documenten
Documenten
0
Ticker
145020.KQ
ISIN
KR7145020004
Hugel SEC Filings
Type | Bericht | Datum |
|---|---|---|
| Geen documenten beschikbaar | ||
Hugel Documenten 2026
Deze pagina bevat alle officiële documenten en SEC-filings voor Hugel aandelen (145020.KQ, ISIN: KR7145020004). Dit omvat jaarverslagen (Formulier 10-K), kwartaalrapporten (Formulier 10-Q) en insidertransacties (Formulier 4). Momenteel zijn 0 documenten beschikbaar. Gegevens worden regelmatig bijgewerkt om beleggers een volledig overzicht van Hugel's regelgevingsfilings te bieden.
Hugel Aandelenanalyse
Hugel Hugel Inc generates revenue by manufacturing and selling biopharmaceuticals based on clostridium botulinum, with products distributed in both domestic and overseas markets. The company’s portfolio includes botulinum toxins available in 50 unit types, 100 unit types, and 200unit types for treating benign essential blepharospasm and improving moderate to severe glabellar lines. Additionally, the firm offers hyaluronic acid fillers designed for the temporary removal of facial wrinkles, specifically the chaeum premium No.1, the chaeum premium No.2, the chaeum premium No.3m, the chaeum premium No.4, the chaeum MID 20A, the chaeum DEEP 20A, the chaeum SUB-Q 20A, and the chaeum VOLUS 20A. Beyond these medical aesthetics, the business also sells wellages, blue roses, and other cosmetics to its customer base.